Proton Therapy and Avastin for Recurrent Glioblastoma
This study is for people with recurrent glioblastoma, a type of brain tumor. Researchers are using a special MRI scan called spectroscopic MRI (sMRI) to find hidden cancer cells. This sMRI scan will help guide radiation therapy, specifically Intensity Modulated Proton Therapy (IMPT), to deliver a higher dose of radiation to the tumor area. You will also receive Bevacizumab (Avastin), a drug given intravenously (through a vein), to help minimize potential side effects. The study aims to see how successful the sMRI-guided therapy is and to monitor for any serious neurological side effects. Anyone aged 18 or older with recurrent glioblastoma may be eligible.
- Study design
- This is an interventional study planning to enroll 96 participants. The study does not specify a phase.
- What's involved
- You will receive radiation therapy (IMPT) over 10 days, 5 days a week for about 2 weeks. Bevacizumab will be given intravenously every 2-3 weeks until your disease progresses.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will measure the success of the sMRI-guided therapy around 60 days. They will also monitor for serious neurological side effects for up to 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jonathan Bell, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage of patients for whom sMRI-guided therapy is technically successfulAbout 60 days
The percentage of participants for whom sMRI-guided therapy is successful will be reported as the percentage of participants who show no significant residual tumor after protocol therapy.
- Incidence of Grade 3 irreversible or any Grade 4/5 neurologic toxicity.Up to 6 months
The incidence of irreversible Grade 3 or any Grade 4/5 neurologic adverse events (AEs) or serious adverse events (SAEs) in study participants will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion. Incidence of these toxicities will be reported for both cohorts, Cohort A (sMRI-Guided RT at 35 Gy in 10 fractions) and Cohort B (sMRI-Guided RT at 40 Gy in 10 fractions).